A guide to what’s new in biotech.
Our team of distinguished journalists have highlighted a diverse collection of biotech original editorial. Below are their picks:
- Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups
- The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes
- Juno halts its immunotherapy trial for cancer after three patient deaths
- What does Donald Trump’s win mean for science and medicine?
- Is Adam Feuerstein the most feared man in biotech?
- Is Theranos finished? Watch for these 5 telltale signs
- Meet one of the world’s most groundbreaking scientists. He’s 34.
- A radically simple idea may open the door to a new world of antibiotics
- Tasty and easy to take, a new ADHD drug alarms some psychiatrics
- There’s new hope for treating hair loss – for women, too
Along with this free content sampler, you’ll also receive a complimentary subscription to ‘Morning Rounds’, STAT’s email newsletter that delivers a daily dose of news in health and medicine.
BONUS OFFER: An exclusive offer for STAT Plus, is awaiting inside the document. STAT Plus, a premium subscription that provides you with access to exclusive, in-depth pharma, biotech, business, and policy coverage, keeping you on top of what’s happening in the industry – as it happens. As a token of our appreciation, we would like to give you a 33% discount off the first year of your STAT Plus subscription – and your first 30 days free!
Simply request the above sampler to receive access to the promo code.
About us: STAT delivers fast, deep, and tough-minded journalism. We take you inside science labs and hospitals, biotech boardrooms, and political backrooms. We dissect crucial discoveries. We examine controversies and puncture hype. We hold individuals and institutions accountable. We introduce you to the power brokers and personalities who are driving a revolution in human health. These are the stores that matter to us all.
Offered Free by: STATNews.com
See All Resources from: STATNews.com
